Jane Street Group LLC Has $77,000 Stake in Actinium Pharmaceuticals, Inc. (NYSE:ATNM)

Jane Street Group LLC lowered its position in shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) by 37.4% during the third quarter, HoldingsChannel.com reports. The fund owned 40,837 shares of the company’s stock after selling 24,392 shares during the quarter. Jane Street Group LLC’s holdings in Actinium Pharmaceuticals were worth $77,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Marshall Wace LLP boosted its position in shares of Actinium Pharmaceuticals by 67.9% during the 2nd quarter. Marshall Wace LLP now owns 256,026 shares of the company’s stock worth $1,895,000 after purchasing an additional 103,557 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in Actinium Pharmaceuticals in the third quarter valued at approximately $322,000. Bank of New York Mellon Corp increased its holdings in shares of Actinium Pharmaceuticals by 28.3% during the second quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock valued at $639,000 after acquiring an additional 19,035 shares in the last quarter. Creative Financial Designs Inc. ADV increased its holdings in shares of Actinium Pharmaceuticals by 183.0% during the third quarter. Creative Financial Designs Inc. ADV now owns 63,785 shares of the company’s stock valued at $120,000 after acquiring an additional 41,250 shares in the last quarter. Finally, Wellington Management Group LLP acquired a new position in shares of Actinium Pharmaceuticals during the third quarter worth approximately $112,000. 27.50% of the stock is currently owned by institutional investors and hedge funds.

Actinium Pharmaceuticals Price Performance

Shares of Actinium Pharmaceuticals stock opened at $1.22 on Thursday. The stock’s fifty day moving average is $1.37. The company has a market capitalization of $38.06 million, a P/E ratio of -0.88 and a beta of 0.12. Actinium Pharmaceuticals, Inc. has a 12-month low of $1.10 and a 12-month high of $10.24.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ATNM. StockNews.com downgraded shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, November 11th. Stephens reaffirmed an “overweight” rating and issued a $5.00 price objective on shares of Actinium Pharmaceuticals in a research note on Tuesday, November 19th. Finally, HC Wainwright reissued a “buy” rating and set a $4.00 target price on shares of Actinium Pharmaceuticals in a research report on Friday, November 15th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $7.40.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).